Page 387 - ESHRE2019
P. 387

 Tuesday, 25 June 2019:
09:50 - 10:50
Product/Educational Theatre ObsEva
Increasing IVF Success with Nolasiban, a New, Oral, Oxytocin Receptor Antagonist
Chair: Juan Garcia Velasco (Spain) Chair: Ernest Loumaye (Switzerland)
Live Birth and Infant Follow-up: Results from a Nolasiban Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial in IVF
Georg Griesinger (Germany)
Reproductive Safety Studies Supporting the Use of Nolasiban in IVF
Oliver Pohl (Switzerland)
The Cost of IVF, Looking Beyond the Obvious
Ben W. Mol (Australia)
    COMPANY SYMPOSIA I VIENNA, AUSTRIA – 23 TO 26 JUNE 2019
387
      COMPANY SYMPOSIA





















































































   385   386   387   388   389